| Acetylcholine Receptor Modulating Antibody | 26474X |
|
 |
||
| This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. | ||
| CPT Code(s): 83519 | Clinical Significance: Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. Modulating Antibody to AChR causes weakness by inhibiting or modulating binding to the receptors. |
|
| Specimen Container: No additive serum separator tube |
| Preferred Specimen: 1 mL serum (0.3 mL minimum) |
| Transport Temperaturer: Refrigerated |
| Methodology: Radiobinding Assay |
| Reference Range: < 32% binding inhibition |
